Login to Your Account

Sarepta stock spikes as golodirsen study suggests inroads on exon 53

By Marie Powers
News Editor

Wednesday, September 6, 2017

Chatter about a potential NDA filing for golodirsen started as soon as Sarepta Therapeutics Inc. reported that the phase I/II study (4053-101) of the exon 53 skipping candidate achieved statistical significance on its primary and secondary biological endpoints.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription